Survey Says Epocrates Enjoys iPhone Success


By Neil Versel

Sept. 16, 2008 | If the iPhone is the killer app that pushes thousands of physicians to adopt health-IT (see “iPhone Will Change Health-IT, Says Datamonitor”), then the Epocrates Rx drug and formulary reference might be the software equivalent. At least that’s what San Mateo, Calif.-based Epocrates is claiming, based on the results of a customer survey.

Some 25,000 U.S. physicians were among the 125,000 users who downloaded the iPhone version of Epocrates Rx in the first month of availability, Epocrates says. And 72 percent of doctors said the availability of the Epocrates software was “important” or “very important” in their decision to buy an iPhone or the related iPod Touch, according to a survey released Monday.

The results may not be too surprising, based on the longstanding popularity of Epocrates reference tools with clinicians. But the company also reports heavy consumer interest in the new product; perhaps 40,000 non-health care professionals downloaded the iPhone software in the first few weeks after its June release.

“We’ve had many more consumers downloading our iPhone application than our other versions,” says Michelle Snyder, vice president of marketing for Epocrates. Snyder attributes this mostly to the high visibility the product has had in the Apple App Store, helping to draw in customers who otherwise would not be aware of Epocrates.

Epocrates was among the first companies to develop third-party applications for the hot-selling iPhone. (See “Epocrates Coming to an iPhone Near You” and “iPhone Is the Apple of Epocrates’ Eye.”) Epocrates surveyed 303 physicians and 304 consumers in August. All downloaded Epocrates Rx for iPhone or iPod Touch during the first week of availability in June, the company says.

Consumers do seem to like having mobile access to health information. According to the survey, 35 percent of consumers with Epocrates Rx for the iPhone report using the software several times a week, and another 54 percent turn to it once a week. Furthermore, nearly two-thirds of consumers have recommended Epocrates to their care providers or plan on doing so in the future.

“Consumers are better monitoring their own care and also managing the care of others,” Snyder says. Indeed, two-thirds of consumers got the Epocrates software to monitor personal conditions. About 23 percent say they were taking care of a relative or friend.

Typical of consumer comments was: “My roommate had a bad allergic reaction to a drug. We contacted her doctor with Epocrates’ information and he changed the medicine.”

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.